← boardnext 2028-04
RCKT
Rocket Pharmaceuticals Inc.distress 5/10 · elevated risk$3.17-4%today-40% from 52w high
Hematology 2
Lead: Danon Disease
Revenue
pre-revenue
Liquidity
$144M
Runway
0.8 yrs
Shares 1y
+1%
Price & events
-16.3% over 6M
CatalystRating changeDilutionFinancingdashed = today
-4.1%
1D
-7.2%
1W
-8.8%
1M
-14.0%
3M
-14.9%
6M
-5.8%
1Y
-87.3%
2Y
-93.1%
5Y
-94.4%
All
Overview
- Market Cap
- $345.60M
- Volume
- 195.54K
- 52 Week Range
- $2.60 – $5.30
- Total Shares
- 109.19M
- Float Shares
- 86.94M
- Short %
- 20.41%
- % Held by Insiders
- 3.10%
- % Held by Institutions
- 89.47%
- RVOL
- 0.08x
- Beta
- 0.45
Pipeline stages · 3 programs
RP-A501
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
RP-L102
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
RP-L301
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 5 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2028-04 Estimated 50% readout ~2028-05-16 | Phase 2 | RP-A501rmatfast trackrare pediatricorphan | Danon Disease | — | recruiting |
| 2026-05-05 | Phase 2 | RP-L102 | Fanconi Anemia Complementation Group A | 5 | active not recruiting |
| 2025-06-09 | Phase 1 | RP-L301 | Pyruvate Kinase Deficiency | 4 | completed |
| 2025-03-24 | Phase 1 | RP-A501rmatfast trackrare pediatricorphan | Danon Disease | 7 | unknown |
| 2025-02 | Phase 2 | RP-L102 | Fanconi Anemia Complementation Group A | 7 | unknown |
Catalyst news & presentations · 9
- 2026-08-06Estimated 45%earningsEarningsEarnings releaseyahoo
- 2026-06-10partnershipSale of Rare Pediatric Disease Priority Review Voucher for $180M to a large pharmaceutical company.SEC 8-K
- 2026-04-26partnershipKRESLADI · Sale of Rare Pediatric Disease Priority Review Voucher for $180MSEC 8-K
- March 28, 2026PDUFAPDUFAKRESLADI · PDUFA target action date for BLA resubmissionSEC 8-K
- 2025trial initiationsecondaryPhase 2RP-L301 · Resumption of patient enrollment in Phase 2 pivotal trial.SEC 8-K
- 2025conferencedata presentationsecondaryPhase 1RP-A501 · Formal update of preliminary long-term follow-up for Patient 1001 at medical conference.SEC 8-K
- 2025-10-03withdrawalRP-L102 · Voluntary withdrawal of BLA for Fanconi AnemiaSEC 8-K
- 2025-08-20fda agreementRP-A501 · FDA lifted clinical hold on Phase 2 trial of RP-A501 for Danon diseaseSEC 8-K
- May 15, 2025conferencedata presentationsecondaryPhase 1RP-A601 · Preliminary Phase 1 data presented at ASGCT.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: 109,193,549 · 0 offerings/1y · 0 PIPEs
- none
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $9 (+197% upside) · 11 analysts
- 2026-05-11Chardan CapitalBuy
- 2026-03-30B of A SecuritiesBuy
- 2026-03-27Chardan CapitalBuy
- 2026-03-02Goldman SachsSell
- 2026-02-27Cantor FitzgeraldOverweight
- 2025-11-18B of A SecuritiesBuy
Competitors — Danon Disease
- none identified
Recent news
- 2026-07-22Rocket Pharmaceuticals stock steadies as gene therapy pipeline advances and cash runway extends - Ad-hoc-news.de
- 2026-07-22RCKT Stock Dives Despite Gene Therapy Approval — Wall Street Dismisses Sell-Off - Stocktwits
- 2026-07-21RCKT Stock Jumps Over 10% Premarket: FDA Approves Its First Gene Therapy For Rare Childhood Immune Disease - Stocktwits
- 2026-07-20ETFs Investing in Rocket Pharmaceuticals, Inc. Stocks - TradingView
- 2026-07-20Enterprise value to EBITDA forward of Rocket Pharmaceuticals, Inc. – DUS:9IP1 - TradingView
- 2026-07-18RCKTW SEC Filings - ROCKET PHARMACEUTICALS INC 10-K, 10-Q, 8-K Forms - Stock Titan
- 2026-07-18Rocket Token Price Today | Live RCKT Price, Chart & Market Data - Binance
- 2026-07-17Betashares Space Industry Etf (ASX: RCKT) Share Price, RCKT Stock News, RCKT Share Price & Updates - Kalkine
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.